AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.05

+1.7%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$898.69M
EPS-1.7400
P/E Ratio-5.20
Earnings Date08/12/2026

spry

Total Assets

Last Annual Value

327.65M

3-Year CAGR

5%

5-Year CAGR

65%

10-Year CAGR

28%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Total Assets

SPRY · NASDAQ
CompanyTotal Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
327.65M
12.0%39.8%N/A 
94.62M
-13.1%-14.3%-10.1%
SVRA logo
Savara Inc.
NASDAQ:SVRA
253.44M
12.6%7.5%24.2%
738.36M
18.0%6.7%26.6%
59.56M
99.1%-17.3%N/A
305.88M
63.2%75.6%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
335.57M
-7.2%52.8%N/A
282.61M
7.8%-1.6%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
175.49M
12.4%32.7%32.0%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.05, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.05